Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

The Future of Nonmetastatic CRPC Management

November 14th 2019

The Impact of Recently Approved AR-Targeted Therapy

November 14th 2019

The PROSPER and ARAMIS Trials in CRPC

November 14th 2019

The SPARTAN Trial Interim Analysis

November 14th 2019

Apalutamide in Treating Nonmetastatic CRPC

November 14th 2019

New OS Data in Treatment for Nonmetastatic CRPC

November 14th 2019

Dr. Vargas on Toxicity of SBRT Versus Standard Radiation in Prostate Cancer

November 13th 2019

Carlos E. Vargas, MD, discusses toxicities associated with stereotactic body radiation therapy compared with standard fractionated radiation therapy in prostate cancer.

Researchers Refining Role of Next-Generation Imaging in Prostate Cancer

November 9th 2019

Phillip J. Koo, MD, discusses the use of conventional imaging as well as the next-generation imaging tools that have the potential to change the management of patients with recurrent prostate cancer.

Dr. Oh on Choosing AR-Targeted Therapy Versus Chemotherapy in mHSPC

November 8th 2019

William K. Oh, MD, discusses factors to consider when choosing a treatment for patients with metastatic hormone-sensitive prostate cancer.

Novel Agents Revolutionize Nonmetastatic CRPC Paradigm

November 5th 2019

Alan H. Bryce, MD, discusses how novel agents have impacted the nonmetastatic castration-resistant prostate cancer space.

Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice

November 1st 2019

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Dr. Mohler on Guidelines for Recording Family History in Prostate Cancer

October 31st 2019

James Mohler, MD, discusses what information should be included in a family history, based on the updated National Comprehensive Cancer Network guidelines for genetic testing in prostate cancer.

Dr. Agarwal on the QoL With Apalutamide in Metastatic Castration-Sensitive Prostate Cancer

October 29th 2019

Neeraj Agarwal, MD, associate professor of medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, University of Utah, discusses quality of life (QoL) with apalutamide (Erleada) in the treatment of patients with metastatic castration-sensitive prostate cancer.

Ongoing Study May Answer Genetic Testing Questions in Prostate Cancer

October 28th 2019

Heather H. Cheng, MD, PhD, discusses the GENTleMEN trial and the widening role of genetic testing for patients with prostate cancer.

Dr. Koo on Next-Generation Imaging in Prostate Cancer

October 25th 2019

Phillip J. Koo, MD, discusses next-generation imaging tools in prostate cancer.

Final Thoughts on Evolving Treatment of Prostate Cancer

October 25th 2019

Optimal Timing for Radium-223 With AR-Targeted Therapy

October 25th 2019

CARD: Sequencing Therapies in Metastatic Prostate Cancer

October 25th 2019

Role of Biomarkers in Metastatic Prostate Cancer

October 25th 2019

PROfound: Olaparib for HRR+ mCRPC

October 25th 2019